Fusion protein capable of degrading amyloid beta peptide

Details for Australian Patent Application No. 2008230177 (hide)

Owner MedImmune Limited

Inventors Andersson, Christin; Freskgard, PerOla

Agent Davies Collison Cave

Pub. Number AU-B-2008230177

PCT Pub. Number WO2008/118093

Priority 60/908,471 28.03.07 US

Filing date 27 March 2008

Wipo publication date 2 October 2008

Acceptance publication date 10 May 2012

International Classifications

C07K 19/00 (2006.01) Hybrid peptides

A61K 38/48 (2006.01) Medicinal preparations containing peptides

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

C12N 9/64 (2006.01) Enzymes, e.g. ligases (6.) - derived from animal tissue, e.g. rennin

Event Publications

1 October 2009 PCT application entered the National Phase

  PCT publication WO2008/118093 Priority application(s): WO2008/118093

3 November 2011 Assignment before Grant

  AstraZeneca AB The application has been assigned to MedImmune Limited

10 May 2012 Application Accepted

  Published as AU-B-2008230177

6 September 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008230182-Junction device, system and method for fluid drainage

2008230174-Cartilage intermediate layer protein 2 C1 and its use to differentiate osteoarthritis from rheumatoid arthritis and non-disease conditions